Ocugen Inc Cash Flow Conversion Efficiency
Ocugen Inc cash flow conversion efficiency. Based on the latest financial reports, Ocugen Inc (OCGN) has a cash flow conversion efficiency ratio of -3.754x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.79 Million) by net assets ($5.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Ocugen Inc (2012–2025)
Cash flow conversion efficiency of Ocugen Inc from 2012 to 2025. This chart illustrates how Ocugen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View OCGN stock price and chart for real-time trading data and today's change.
Ocugen Inc Cash Flow Conversion Ratio Explained
Ocugen Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Ocugen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ocugen Inc ranked by their cash flow conversion efficiency. Also see Ocugen Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CSLM Digital Asset Acquisition Corp III, Ltd
NASDAQ:KOYN
|
-0.001x |
|
The Lovesac Company
NASDAQ:LOVE
|
-0.172x |
|
VT GMP Co.Ltd
KQ:018290
|
-0.043x |
|
SILENCE THERAP. SP.ADR/1
F:XRP2
|
-0.277x |
|
K-Fast Holding AB (publ)
ST:KFAST-B
|
0.004x |
|
Boryszew SA
WAR:BRS
|
0.012x |
|
Sonix Technology Co Ltd
TW:5471
|
0.044x |
|
Seneca Foods Corp B
NASDAQ:SENEB
|
0.044x |
Annual Cash Flow Conversion Efficiency for Ocugen Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Ocugen Inc from 2012 to 2025. Review Ocugen Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-12.17 Million | $-56.96 Million | 4.682x | +429.23% |
| 2024-12-31 | $29.63 Million | $-42.14 Million | -1.422x | +7.03% |
| 2023-12-31 | $40.56 Million | $-62.05 Million | -1.530x | -88.38% |
| 2022-12-31 | $73.98 Million | $-60.08 Million | -0.812x | -62.31% |
| 2021-12-31 | $95.82 Million | $-47.94 Million | -0.500x | +26.70% |
| 2020-12-31 | $21.55 Million | $-14.71 Million | -0.683x | +55.48% |
| 2019-12-31 | $11.02 Million | $-16.89 Million | -1.533x | -104.45% |
| 2018-12-31 | $-458.00K | $-15.78 Million | 34.448x | +1586.17% |
| 2017-12-31 | $-11.27 Million | $-23.02 Million | 2.043x | +207.70% |
| 2016-12-31 | $13.57 Million | $-25.74 Million | -1.897x | -78.10% |
| 2015-12-31 | $28.20 Million | $-30.03 Million | -1.065x | -213.69% |
| 2014-12-31 | $54.21 Million | $-18.41 Million | -0.340x | -267.87% |
| 2013-12-31 | $-75.55 Million | $-15.28 Million | 0.202x | -67.41% |
| 2012-12-31 | $-19.71 Million | $-12.23 Million | 0.621x | -- |
About Ocugen Inc
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase… Read more